Fox Business - The Power to Prosper
Search Site

Synthes Holding AG

Related Topics

  1. Johnson & Johnson
  2. Johnson Controls
  3. Thomas A. James
  4. William D. Johnson
  5. Kevin Johnson
  6. Stifel Nicolaus
Get updates on Synthes Holding AG
J&J tops estimates as prescription, OTC drugs shine

Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicines that had been recalled over quality control problems.Newer prescription medicines, including prostate cancer drug Zytiga, psoriasis drug Stelara, and Incivo for hepatitis C made big contributions.J&J shares rose 1.7 percent to $83.13 in mid-day trading."Overall, the company's first-quarter performance was clearly a positive, with pharmaceuticals firing on all cylinders and more than making up for disappointment with medical devices," said Edward Jones analyst Judson Clark. He was also optimistic that over-the-counter medicines would continue to regain lost ground this year.U.S. sales of over-the-counter (OTC) medicines, including painkillers Tylenol and Motrin, jumped 14 percent, allowing the broader consumer products business to eke out a 2.4 percent sales gain in the quarter."It's a strong start to the year that increas...

Read More ›

  1. J&J Trims Executives' 2012 Bonuses by 10%, Citing Mixed Results

    Johnson & Johnson's (JNJ) "mixed" performance in 2012 prompted its board to reduce the planned bonus for Chief Executive Alex Gorsky and other senior officers by 10%...

  2. J&J 4th-Quarter Profit Soars On Fewer Charges, Synthes Buy

    Johnson & Johnson (JNJ) reported a surge in fourth-quarter earnings from a year-earlier period that was weighed down by legal costs, while an acquisition helped sale...

  3. Johnson & Johnson Profit Soars

    Johnson & Johnson's (JNJ) fourth-quarter earnings soared from a year-earlier period that included $2.9 billion in charges for hip product recalls, litigation losses ...

  4. J&J's 4Q Beats, Outlook Disappoints

    Johnson & Johnson (NYSE:JNJ) recorded higher fourth-quarter sales that were fueled by its acquisition of Synthes last year, just beating Wall Street's earnings proje...

  5. WEEK AHEAD: Fourth-Quarter Earnings Season Ramps Up

    Fourth-quarter earnings kick off in earnest next week, with reports due from technology majors Apple Inc. (AAPL), Google Inc. (GOOG) and International Business Machi...

  6. J&J CEO Gorsky to Be Chairman, as Weldon Will Retire in 2013

    Johnson & Johnson (JNJ) named its new chief executive, Alex Gorsky, as its new chairman, completing a leadership transition for the health-care conglomerate as its f...

  7. J&J profit beats as newer drugs, devices deliver

    Healthcare giant Johnson & Johnson reported better-than-expected third-quarter results on Tuesday, as newer drugs, including a treatment for prostate cancer, led a r...

  8. J&J 3rd-Quarter Profit Fell 7.3% Amid Acquisition-Related Costs

    Johnson & Johnson's (JNJ) third-quarter profit fell 7.3% on acquisition and research costs, while the recent purchase of medical-device maker Synthes fueled a 6.5% r...

  9. J&J third-quarter profit beats as drugs, devices deliver

    Johnson & Johnson reported better-than-expected quarterly results on Tuesday, as prescription drug sales rebounded with the help of newer products and jitters about ...

  10. Johnson & Johnson Profit Dips, Sales Increase

    Johnson & Johnson said Tuesday its third-quarter profit fell to $3 billion, or $1.05 a share, from $3.2 billion, or $1.15 a share, in the year-ago period. Adjusted p...

  11. Johnson & Johnson Tops Street in 3Q, Lifts Outlook

    Johnson & Johnson (NYSE:JNJ) posted stronger-than-expected third-quarter earnings and raised its fiscal 2012 outlook Tuesday as drug sales ramped up in the U.S.The m...

  12. EARNINGS PREVIEW: U.S. Drug Makers Struggle With Loss of Exclusivity in 3rd Quarter

    TAKING THE PULSE: Most major U.S. drug makers in the third quarter continued with efforts to cope with the recent losses of market exclusivity for former blockbuster...

  1. J&J Sales Rise, Helped By Return of Recalled Products

    Johnson & Johnson (JNJ) reported an 8.5% increase in first-quarter revenue, helped by a medical-device acquisition, higher drug sales and the return to market of som...

  2. J&J tops estimates on strong prescription drug sales

    Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicine...

  3. J&J 1st-Quarter Profit Off 11% on Litigation Costs

    Johnson & Johnson (JNJ) reported a 10.6% decline in first-quarter profit as a result of litigation and other expenses, while a medical-device acquisition and higher ...

  4. Strong Drug Sales Lift J&J Above Street in 1Q

    Johnson & Johnson (NYSE:JNJ) reported surprising first-quarter earnings on Tuesday as demand for its global specialty and over-the-counter drugs increased and sales ...

  5. J&J Profit Off 11% on Litigation, Acquisitions

    Johnson & Johnson's (JNJ) first-quarter earnings fell 11% on litigation expenses, impacts related to its Synthes Inc. acquisition and other items, though the acquisi...

  6. J&J 1st-Quarter Profit Off 11% on Litigation Expenses, Acquisition-Related Items

    Johnson & Johnson's (JNJ) first-quarter earnings fell 11% on litigation expenses, impacts related to its Synthes Inc. acquisition and other items, though the acquisi...

  7. J&J Trims Executives' 2012 Bonuses by 10%

    Johnson & Johnson's (JNJ) "mixed" performance in 2012 prompted its board to reduce the planned bonus for Chief Executive Alex Gorsky and other senior officers by 10%...

‹ Prev123Next ›
Freebase CC-BY
Source: Synthes Holding AG on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL